French Maritime Pine Bark for Blood Pressure and Heart Health

Table of Contents

1. The Endothelium: The Core of the Story
2. Endothelial Function Trials
3. Coronary Artery Disease: The Independent Trial
4. Blood Pressure: What the Meta-Analyses Show
5. Platelets and the Smoker Studies
6. Cholesterol, Blood Sugar, and Diabetes
7. Erectile Function: Endothelium Below the Belt
8. Practical Use and Expectations
9. Cautions and the Evidence Caveat
10. Key Research Papers
11. External Resources
12. Connections
13. Featured Videos

The Endothelium: The Core of the Story

The endothelium is the single layer of cells lining every blood vessel. Far from being passive plumbing, it is an active organ: it releases nitric oxide, a gas that signals the vessel wall to relax and widen, keeps blood flowing smoothly, discourages clots, and calms inflammation. When the endothelium works poorly — a state called endothelial dysfunction — vessels stay too constricted, blood pressure rises, and the earliest steps of atherosclerosis begin. Endothelial dysfunction is one of the earliest measurable warning signs of cardiovascular disease, often present years before a heart attack.

The standardized extract's central cardiovascular mechanism is that its procyanidins stimulate endothelial nitric oxide synthase (eNOS), the enzyme that makes nitric oxide, so the endothelium produces more of it. Fitzpatrick and colleagues (1998) showed this endothelium-dependent, nitric-oxide-mediated relaxation of blood vessels in the laboratory. Because so many cardiovascular outcomes trace back to endothelial health, an agent that improves it could, in principle, help blood pressure, arterial flow, and clotting all at once — the same “one mechanism, many effects” theme seen across the extract's uses.

Back to Table of Contents

Endothelial Function Trials

Several human trials have measured endothelial function directly, usually with flow-mediated dilation (FMD) — an ultrasound test of how much an artery widens when blood flow surges, a standard proxy for nitric-oxide availability:

• Liu and colleagues (2004) reported that French maritime pine bark extract improved endothelial function in hypertensive patients.
• Nishioka and colleagues (2007) reported that the extract augmented endothelium-dependent vasodilation in humans, tying the clinical effect to nitric oxide.
• Hu and colleagues (2015) found improved endothelial function in people with borderline hypertension, hyperlipidemia, and hyperglycemia.

The direction is consistent: across different populations, pine bark extract tends to improve this measure of arterial health. That consistency, and the fact that the effect is mechanistically expected, make endothelial function the most credible cardiovascular benefit — especially once an independent trial is added to the picture.

Back to Table of Contents

Coronary Artery Disease: The Independent Trial

Most research on this extract comes from a small circle of investigators, often with manufacturer involvement, so an independent trial carries extra weight. Enseleit and colleagues (2012), based at a Swiss university hospital, ran a double-blind, randomized, placebo-controlled, cross-over study in patients with stable coronary artery disease and published it in the European Heart Journal. The extract significantly improved flow-mediated dilation — i.e., endothelial function — compared with placebo.

This is arguably the highest-quality piece of cardiovascular evidence for the extract: an independent group, a rigorous design, a hard physiological endpoint, and a respected journal. It is important to read it precisely, though. It demonstrated that the extract improves the function of the artery lining in people who already have coronary disease. It did not show that the extract prevents heart attacks, reduces deaths, or replaces any cardiac medication — those questions were not what the trial tested, and no study has answered them. Improved endothelial function is a promising surrogate marker, not a proven outcome.

Back to Table of Contents

Blood Pressure: What the Meta-Analyses Show

Because better endothelial function should relax arteries, several trials looked at blood pressure, and two systematic reviews pooled them. Pourmasoumi and colleagues (2020) and Fogacci and colleagues (2020) each meta-analyzed randomized, placebo-controlled trials of pine bark extract on blood pressure. Both found modest reductions — on the order of a few millimeters of mercury — with the reviews differing somewhat on exactly which numbers reached statistical significance (systolic, diastolic, or both).

The summary from these reviews: pine bark extract produces a small, real, but clinically minor blood-pressure effect. A drop of a couple of mmHg is not nothing at a population level, but it is far weaker than antihypertensive medication, and the meta-analyses do not show an effect large enough to control diagnosed hypertension. The pooled data point, at most, to a marginal role alongside lifestyle change in people with borderline readings; for people already taking blood-pressure drugs, the relevant finding is a possible additive effect on readings.

Back to Table of Contents

Platelets and the Smoker Studies

Platelets are the blood cells that clump to form clots; overactive platelets contribute to heart attacks and strokes. Pütter and colleagues (1999) studied smokers, whose platelets are abnormally sticky, and found that the extract reduced smoking-induced platelet aggregation. Notably, in that study a single dose of the extract was comparable to aspirin for this specific measure, while having less effect on prolonging bleeding time.

This antiplatelet signal is a double-edged sword. On one hand it fits the cardiovascular-protective theme and may partly explain the flight-thrombosis findings on the Circulation & Veins page. On the other hand, it is precisely why the research raises a concern about combining the extract with blood thinners and about use before surgery — a mild antiplatelet effect can stack on top of aspirin, clopidogrel, or an anticoagulant.

Back to Table of Contents

Cholesterol, Blood Sugar, and Diabetes

Cardiovascular risk is more than blood pressure, and the extract has been tested on several other risk factors, especially in type 2 diabetes:

• Lipids. Devaraj and colleagues (2002) reported that a polyphenol-rich pine bark extract raised plasma antioxidant capacity and improved the lipoprotein profile — lowering LDL (“bad”) cholesterol and, in their data, nudging HDL (“good”) cholesterol up.
• Cardiovascular risk factors in diabetes. Zibadi and colleagues (2008) found that pine bark extract supplementation reduced several cardiovascular risk factors in people with type 2 diabetes.
• Blood sugar. Liu and colleagues (2004) reported an antidiabetic effect — lower fasting glucose — in patients with type 2 diabetes, plausibly through the same microvascular and antioxidant mechanisms, and consistent with the retinal-microcirculation benefits in early diabetic retinopathy.

These are supportive signals, mostly from small studies. They suggest the extract touches several cardiovascular risk factors gently rather than powerfully — an adjunct picture, not a replacement for statins, blood-pressure medication, or diabetes therapy.

Back to Table of Contents

Erectile Function: Endothelium Below the Belt

Erections are a nitric-oxide and endothelial event, so it is logical that the extract has been studied there too, usually combined with the amino acid L-arginine (a nitric-oxide precursor) in a combination product. Stanislavov and colleagues (2008) reported improved erectile function with this combination in a randomized, placebo-controlled cross-over trial. Because the studied product pairs the pine bark extract with arginine, the benefit cannot be attributed to the extract alone, and this remains a modest, industry-linked evidence base — but it is a neat illustration that the through-line of pine bark extract's cardiovascular story is endothelial nitric oxide. For the condition itself, see Erectile Dysfunction.

Back to Table of Contents

Practical Use and Expectations

Most cardiovascular trials used a single standardized extract sold under the trademarked name Pycnogenol; results may not transfer to other pine bark products. Doses were generally roughly 100–200 mg per day (sometimes divided), for several weeks to a few months. As with the other uses, effects built gradually and were typically assessed over 8–12 weeks.

The benefit reported in these trials is modest support of vascular health: somewhat better endothelial function, a small blood-pressure nudge, gentle effects on lipids and platelets. Pine bark extract is not an established treatment for diagnosed hypertension, high cholesterol, coronary disease, or diabetes, and no study has shown it can replace prescribed cardiovascular medication. In these conditions the evidence supports, at most, a possible add-on role; decisions about medicines and supplements belong with a clinician.

Back to Table of Contents

Cautions and the Evidence Caveat

• Interactions with cardiovascular drugs. Because pine bark extract can lower blood pressure and reduce platelet stickiness, it may add to the effect of antihypertensives, anticoagulants, and antiplatelet drugs. The signs this raises are lower blood-pressure readings and easy bruising or bleeding; decisions about combinations belong with a clinician.
• Surgery. Because of the antiplatelet effect, the research raises a concern about use in the week or two before any procedure.
• Surrogate markers, not outcomes. Improved endothelial function and small blood-pressure changes are promising signs, not proof of fewer heart attacks or longer life. No trial has shown pine bark extract reduces cardiovascular events.
• Evidence quality. The 2020 Cochrane review judged the overall evidence low quality; the Enseleit (2012) coronary trial is the standout independent exception. The independent, blinded studies carry the most weight.
• Diagnosed disease. Diabetes, hypertension, and coronary disease are managed medically; the evidence supports, at most, an adjunct role for the extract.

Back to Table of Contents

Key Research Papers

1. Enseleit F et al. (2012). Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study. European Heart Journal — Search PubMed
2. Liu X et al. (2004). Pycnogenol, French maritime pine bark extract, improves endothelial function of hypertensive patients. Life Sciences — PubMed PMID: 14659974
3. Nishioka K et al. (2007). Pycnogenol, French maritime pine bark extract, augments endothelium-dependent vasodilation in humans. Hypertension Research — PubMed PMID: 18037769
4. Hu S et al. (2015). Effects of Pycnogenol on endothelial dysfunction in borderline hypertensive, hyperlipidemic, and hyperglycemic individuals: the borderline study. International Angiology — PubMed PMID: 25391252
5. Fitzpatrick DF, Bing B, Rohdewald P (1998). Endothelium-dependent vascular effects of Pycnogenol. Journal of Cardiovascular Pharmacology — PubMed PMID: 9781917
6. Pourmasoumi M et al. (2020). Effect of pycnogenol supplementation on blood pressure: a systematic review and meta-analysis of clinical trials. Phytotherapy Research — PubMed PMID: 31637782
7. Fogacci F et al. (2020). Effect of Pycnogenol on blood pressure: findings from a PRISMA-compliant systematic review and meta-analysis. Angiology — PubMed PMID: 31763928
8. Pütter M et al. (1999). Inhibition of smoking-induced platelet aggregation by aspirin and Pycnogenol. Thrombosis Research — PubMed PMID: 10498385
9. Zibadi S et al. (2008). Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation. Nutrition Research — PubMed PMID: 19083426
10. Liu X et al. (2004). Antidiabetic effect of Pycnogenol French maritime pine bark extract in patients with diabetes type II. Life Sciences — PubMed PMID: 15363656
11. Devaraj S et al. (2002). Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile. Lipids — PubMed PMID: 12530550
12. Stanislavov R et al. (2008). Improvement of erectile function with Prelox: a randomized, double-blind, placebo-controlled, crossover trial. International Journal of Impotence Research — PubMed PMID: 17703218
13. Robertson NU et al. (2020). Pine bark (Pinus spp.) extract for treating chronic disorders. Cochrane Database of Systematic Reviews — PubMed PMID: 32990945

PubMed Topic Searches

1. PubMed: Pycnogenol endothelial function
2. PubMed: Pycnogenol blood pressure meta-analysis
3. PubMed: Pycnogenol platelet aggregation
4. PubMed: Pycnogenol type 2 diabetes
5. PubMed: Pycnogenol nitric oxide

Back to Table of Contents

External Resources

• Search PubMed
• Drugs.com — pine bark extract monograph (uses, dosing, interactions)
• PubMed — pine bark extract and cardiovascular health

Back to Table of Contents

Connections

• French Maritime Pine Bark Benefits Hub
• Pine Bark for Circulation & Veins
• Pine Bark: Standardization & Safety
• French Maritime Pine Bark (Main Page)
• Hypertension
• Atherosclerosis
• Type 2 Diabetes
• Erectile Dysfunction
• Arginine (nitric oxide)
• CoQ10 (heart antioxidant)
• Resveratrol
• All Antioxidants

Back to Table of Contents

Featured Videos